Skip to main content Back to Top
Advertisement

12/2/2022

Oseltamivir Oral Suspension and Capsules

Products Affected - Description

    • Oseltamivir oral capsule, Amneal, 30 mg, unit-dose blister pack, 10 count, NDC 69238-1264-01
    • Oseltamivir oral capsule, Amneal, 45 mg, unit-dose blister pack, 10 count, NDC 69238-1265-01
    • Oseltamivir oral capsule, Amneal, 75 mg, unit-dose blister pack, 10 count, NDC 69238-1266-01
    • Oseltamivir oral capsule, Camber, 30 mg, unit-dose blister pack, 10 count, NDC 31722-0630-31
    • Oseltamivir oral capsule, Camber, 45 mg, unit-dose blister pack, 10 count, NDC 31722-0631-31
    • Oseltamivir oral capsule, Camber, 75 mg, unit-dose blister pack, 10 count, NDC 31722-0632-31
    • Oseltamivir oral capsule, Macleods, 30 mg, unit-dose blister pack, 10 count, NDC 33342-0256-66
    • Oseltamivir oral capsule, Macleods, 75 mg, unit-dose blister pack, 10 count, NDC 33342-0258-66
    • Oseltamivir oral powder for suspension, Teva, 6 mg/mL, 60 mL bottle, 1 count, NDC 00093-8180-64
    • Oseltamivir oral powder for suspension, Zydus, 6 mg/mL, 60 mL bottle, 1 count, NDC 70710-1165-06

Reason for the Shortage

    • Ajanta has oseltamivir available to contracted customers.
    • Alembic has oseltamivir available to contracted customers.
    • Alvogen has oseltamivir suspension and capsules available.
    • Amneal did not provide a reason for the shortage.
    • Camber did not provide a reason for the shortage.
    • Genentech has Tamiflu presentations available and is reviewing orders.
    • Macleod's was not available to provide updated information.
    • Strides has oseltamivir capsules available.
    • Teva did not provide a reason for the shortage.
    • Zydus did not provide a reason for the shortage.

Available Products

    • Tamiflu oral capsule, Genentech, 30 mg, unit-dose blister pack, 10 count, NDC 00004-0802-85
    • Tamiflu oral capsule, Genentech, 45 mg, unit-dose blister pack, 10 count, NDC 00004-0801-85
    • Tamiflu oral capsule, Genentech, 75 mg, unit-dose blister pack, 10 count, NDC 00004-0800-85
    • Tamiflu oral powder for suspension, Genentech, 6 mg/mL, 60 mL bottle, 1 count, NDC 00004-0822-05
    • Oseltamivir oral powder for suspension, Ajanta, 6 mg/mL, 60 mL bottle, 1 count, NDC 27241-0139-09
    • Oseltamivir oral capsule, Alembic, 30 mg, unit-dose blister pack, 10 count, NDC 62332-0413-10
    • Oseltamivir oral capsule, Alembic, 45 mg, unit-dose blister pack, 10 count, NDC 62332-0414-10
    • Oseltamivir oral capsule, Alembic, 75 mg, unit-dose blister pack, 10 count, NDC 62332-0415-10
    • Oseltamivir oral capsule, Alvogen, 30 mg, unit-dose blister pack, 10 count, NDC 47781-0468-13
    • Oseltamivir oral capsule, Alvogen, 45 mg, unit-dose blister pack, 10 count, NDC 47781-0469-13
    • Oseltamivir oral capsule, Alvogen, 75 mg, unit-dose blister pack, 10 count, NDC 47781-0470-13
    • Oseltamivir oral powder for suspension, Alvogen, 6 mg/mL, 60 mL bottle, 1 count, NDC 47781-0384-26
    • Oseltamivir oral powder for suspension, Amneal, 6 mg/mL, 60 mL bottle, 1 count, NDC 69238-1273-06
    • Oseltamivir oral capsule, Macleods, 45 mg, unit-dose blister pack, 10 count, NDC 33342-0257-66
    • Oseltamivir oral capsule, Strides Pharma, 30 mg, unit-dose blister pack, 10 count, NDC 64380-0797-01
    • Oseltamivir oral capsule, Strides Pharma, 45 mg, unit-dose blister pack, 10 count, NDC 64380-0798-01
    • Oseltamivir oral capsule, Strides Pharma, 75 mg, unit-dose blister pack, 10 count, NDC 64380-0799-01

Estimated Resupply Dates

    • Amneal has oseltamivir 30 mg, 45 mg, and 75 mg capsules on back order and the company cannot estimate a release date.
    • Camber has oseltamivir 30 mg, 45 mg, and 75 mg capsules on allocation.
    • Teva has oseltamivir 6 mg/mL powder for suspension in 60 mL bottles on back order and the company estimates a release date of late-December 2022.
    • Zydus has oseltamivir 6 mg/mL powder for suspension in 60 mL bottles on allocation.

Updated

Updated December 2, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 1, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.